FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Douglas Biedenbach

Research Profile

Procedures

Microbial Sensitivity Tests

Chemicals & Drugs

Living Beings

Physiology

Geographic Areas

Concepts & Ideas

Sensitivity and Specificity

Co-author Network

Publications

TOP 3
Rodrigo E Mendes; Helio S Sader; M R K Alley; Douglas J Biedenbach; Ronald N Jones
Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli.
Stephen P Hawser; Daryl J Hoban; Robert E Badal; Douglas J Biedenbach; Samuel K Bouchillon; Rafael Cantón; David L Paterson
Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.
Douglas J Biedenbach; Ronald N Jones; Lisa L Turner; David J Farrell
Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Douglas Biedenbach (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Rodrigo E Mendes; Helio S Sader; M R K Alley; Douglas J Biedenbach; Ronald N Jones
Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli.
Antimicrobial agents and chemotherapy 2013;57(6):2849-57.
2013: Stephen P Hawser; Daryl J Hoban; Robert E Badal; Douglas J Biedenbach; Samuel K Bouchillon; Rafael Cantón; David L Paterson
Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.
International journal of antimicrobial agents 2013;41(3):224-8.
2012: Douglas J Biedenbach; Ronald N Jones; Lisa L Turner; David J Farrell
Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains.
Diagnostic microbiology and infectious disease 2012;74(2):204-6.
2012: Helio S Sader; Franz J Schmitz; Douglas J Biedenbach; Zrinka Ivezic-Schoenfeld; Susanne Paukner; Ronald N Jones
Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).
The Journal of antimicrobial chemotherapy 2012;67(5):1170-5.
2012: Douglas J Biedenbach; David J Farrell; Robert K Flamm; Lisa C Liverman; Gail McIntyre; Ronald N Jones
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
International journal of antimicrobial agents 2012;39(4):321-5.
2012: Helio S Sader; Susanne Paukner; Douglas J Biedenbach; Zrinka Ivezic-Schoenfeld; Ronald N Jones
Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.
Antimicrobial agents and chemotherapy 2012;56(3):1619-23.
2011: David J Farrell; Robert K Flamm; Douglas J Biedenbach; Lisa C Liverman; Ronald N Jones
Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2011;71(4):415-20.
2011: David J Farrell; Douglas J Biedenbach; Lisa C Liverman; Ronald N Jones
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
Antimicrobial agents and chemotherapy 2011;55(7):3631-4.
2011: David J Farrell; Shan Putnam; Douglas J Biedenbach; Luigi Moro; Roberta Bozzella; Giuseppe Celasco; Ronald N Jones
In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
Antimicrobial agents and chemotherapy 2011;55(3):992-6.
2011: Shan Putnam; Helio S Sader; David J Farrell; Douglas J Biedenbach; Mariana Castanheira
Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.
International journal of antimicrobial agents 2011;37(1):39-45.
2010: Douglas J Biedenbach; David J Farrell; Rodrigo E Mendes; James E Ross; Ronald N Jones
Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.
Diagnostic microbiology and infectious disease 2010;68(4):459-67.
2010: Ronald N Jones; Douglas J Biedenbach; Patricia M Roblin; Stephan A Kohlhoff; Margaret R Hammerschlag
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
Antimicrobial agents and chemotherapy 2010;54(10):4518-9.
2010: Douglas J Biedenbach; Mariana Castanheira; Ronald N Jones
Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
Antimicrobial agents and chemotherapy 2010;54(9):4009-11.
2010: David J Farrell; Helio S Sader; Mariana Castanheira; Douglas J Biedenbach; Paul R Rhomberg; Ronald N Jones
Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
International journal of antimicrobial agents 2010;35(6):537-43.
2010: Douglas J Biedenbach; Paul R Rhomberg; Rodrigo E Mendes; Ronald N Jones
Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102).
Diagnostic microbiology and infectious disease 2010;66(3):301-7.
2010: John B Bremner; Paul A Keller; Stephen G Pyne; Timothy P Boyle; Zinka Brkic; Dorothy M David; Adel Garas; Jody Morgan; Mark Robertson; Kittiya Somphol; Michael H Miller; Adam S Howe; Paul Ambrose; Sujata Bhavnani; Thomas R Fritsche; Douglas J Biedenbach; Ronald N Jones; Robert W Buckheit; Karen M Watson; Dean Baylis; Jonathan A Coates; John Deadman; Dharshini Jeevarajah; Andrea McCracken; David I Rhodes
Binaphthyl-based dicationic peptoids with therapeutic potential.
Angewandte Chemie (International ed. in English) 2010;49(3):537-40.
2009: Dilip Mathai; Douglas J Biedenbach; Ronald N Jones; Jan M Bell; John Turnidge; Helio S Sader
Activity of daptomycin against gram-positive bacterial isolates from Indian medical centres (2006-2007).
International journal of antimicrobial agents 2009;34(5):497-9.
2009: Milagros P Reyes; Ammar Ali; Rodrigo E Mendes; Douglas J Biedenbach
Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008.
Medicine 2009;88(5):294-301.
2009: Douglas J Biedenbach; Ronald N Jones
Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Diagnostic microbiology and infectious disease 2009;64(2):202-12.
2009: Douglas J Biedenbach; Ronald N Jones
Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Diagnostic microbiology and infectious disease 2009;64(2):177-84.
2009: Ronald N Jones; Douglas J Biedenbach; Helio S Sader
In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects.
Diagnostic microbiology and infectious disease 2009;63(3):339-41.
2009: Douglas J Biedenbach; Jan M Bell; Helio S Sader; John D Turnidge; Ronald N Jones
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
Antimicrobial agents and chemotherapy 2009;53(3):1260-3.
2009: Thomas R Fritsche; Douglas J Biedenbach; Ronald N Jones
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
Antimicrobial agents and chemotherapy 2009;53(3):1221-4.
2008: Ronald Jones; Douglas J Biedenbach; Paul G Ambrose; Matthew A Wikler
Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.
Diagnostic microbiology and infectious disease 2008;62(1):110-2.
2008: Douglas J Biedenbach; Ronald Jones; Thomas R Fritsche
Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.
Diagnostic microbiology and infectious disease 2008;61(2):240-4.
2008: Thomas R Fritsche; Douglas J Biedenbach; Ronald Jones
Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006).
Journal of chemotherapy (Florence, Italy) 2008;20(2):170-4.
2007: Douglas J Biedenbach; Jan M Bell; Helio S Sader; Thomas R Fritsche; Ronald Jones; John D Turnidge
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
International journal of antimicrobial agents 2007;30(2):143-9.
2007: Lalitagauri M Deshpande; Thomas R Fritsche; Gary J Moet; Douglas J Biedenbach; Ronald Jones
Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program.
Diagnostic microbiology and infectious disease 2007;58(2):163-70.
2007: Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald Jones
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
Journal of clinical microbiology 2007;45(3):998-1004.
2007: Gary J Moet; Ronald Jones; Douglas J Biedenbach; Matthew G Stilwell; Thomas R Fritsche
Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Diagnostic microbiology and infectious disease 2007;57(1):7-13.
2006: Kelley A Fedler; Douglas J Biedenbach; Ronald Jones
Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
Diagnostic microbiology and infectious disease 2006;56(4):427-36.
2006: Holly K Huynh; Douglas J Biedenbach; Ronald Jones
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
Diagnostic microbiology and infectious disease 2006;55(3):241-3.
2006: Douglas J Biedenbach; Mark Toleman; Timothy R Walsh; Ronald Jones
Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Diagnostic microbiology and infectious disease 2006;55(2):119-27.
2006: Beth P Goldstein; Ronald Jones; Thomas R Fritsche; Douglas J Biedenbach
Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
Diagnostic microbiology and infectious disease 2006;54(2):83-7.
2006: Ronald Jones; Qing Li; Bruce Kohut; Douglas J Biedenbach; Jan Bell; John D Turnidge
Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia.
Diagnostic microbiology and infectious disease 2006;54(1):63-71.
2006: Douglas J Biedenbach; Mark Toleman; Timothy R Walsh; Ronald Jones
Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Diagnostic microbiology and infectious disease 2006;54(1):13-21.
2005: Ronald Jones; Douglas J Biedenbach; Helio S Sader; Thomas R Fritsche; Mark Toleman; Timothy R Walsh
Emerging epidemic of metallo-beta-lactamase-mediated resistances.
Diagnostic microbiology and infectious disease 2005;51(2):77-84.
2005: Joseph R DiPersio; Lalitagauri M Deshpande; Douglas J Biedenbach; Mark Toleman; Timothy R Walsh; Ronald Jones
Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003).
Diagnostic microbiology and infectious disease 2005;51(1):1-7.
2005: Helio S Sader; Douglas J Biedenbach; Jennifer M Streit; Ronald Jones
Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections.
International journal of antimicrobial agents 2005;25(1):89-92.
2004: Douglas J Biedenbach; Gary J Moet; Ronald Jones
Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
Diagnostic microbiology and infectious disease 2004;50(1):59-69.
2004: Ronald Jones; Holly K Huynh; Douglas J Biedenbach
Activities of doripenem (S-4661) against drug-resistant clinical pathogens.
Antimicrobial agents and chemotherapy 2004;48(8):3136-40.
2004: Ronald Jones; Holly K Huynh; Douglas J Biedenbach; Thomas R Fritsche; Helio S Sader
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
The Journal of antimicrobial chemotherapy 2004;54(1):144-54.
2003: Douglas J Biedenbach; Ronald Jones
Revision of linezolid disk diffusion quality control guidelines for testing Staphylococcus aureus ATCC 25923: an independent seven-laboratory trial.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(10):1035-7.
2003: D M Johnson; Helio S Sader; Thomas R Fritsche; Douglas J Biedenbach; Ronald Jones
Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2003;47(1):373-6.
2003: Helio S Sader; Douglas J Biedenbach; Ronald Jones
Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001).
Diagnostic microbiology and infectious disease 2003;47(1):361-4.
2003: Douglas J Biedenbach; Jennifer M Stephen; Ronald Jones
Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program--North America, 2001.
Diagnostic microbiology and infectious disease 2003;46(4):291-4.
2003: Kelley A Gordon; Douglas J Biedenbach; Ronald Jones
Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2003;46(4):285-9.
2003: Tamara R Anderegg; Douglas J Biedenbach; Ronald Jones
Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor.
International journal of antimicrobial agents 2003;22(1):84-6.
2003: Tamara R Anderegg; Douglas J Biedenbach; Ronald Jones
Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2003;46(2):147-50.
2003: Tamara R Anderegg; Douglas J Biedenbach; Ronald Jones
Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.
Journal of clinical microbiology 2003;41(6):2795-6.
2003: Ronald Jones; Douglas J Biedenbach; Mondell L Beach
Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2003;46(1):77-80.
2003: Alan H Mutnick; Douglas J Biedenbach; Ronald Jones
Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2003;46(1):63-8.
2003: Douglas J Biedenbach; Ronald Jones
Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program.
Diagnostic microbiology and infectious disease 2003;46(1):55-61.
2003: Daryl J Hoban; Douglas J Biedenbach; Alan H Mutnick; Ronald Jones
Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000).
Diagnostic microbiology and infectious disease 2003;45(4):279-85.
2003: Ronald Jones; Douglas J Biedenbach
Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
Diagnostic microbiology and infectious disease 2003;45(4):273-8.
2003: Ronald Jones; Douglas J Biedenbach; Ana Gales
Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).
International journal of antimicrobial agents 2003;21(1):1-7.
2002: Dilip Mathai; Paul R Rhomberg; Douglas J Biedenbach; Ronald Jones
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories.
Diagnostic microbiology and infectious disease 2002;44(4):367-77.
2002: Ronald Jones; Lalitagauri M Deshpande; Alan H Mutnick; Douglas J Biedenbach
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
The Journal of antimicrobial chemotherapy 2002;50(6):915-32.
2002: Wen-Liang Yu; Ronald Jones; Richard J Hollis; Shawn A Messer; Douglas J Biedenbach; Lalitagauri M Deshpande; Michael A Pfaller
Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.
Journal of clinical microbiology 2002;40(12):4666-9.
2002: Helio S Sader; Ronald Jones; Soraya Andrade-Baiocchi; Douglas J Biedenbach
Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers.
Diagnostic microbiology and infectious disease 2002;44(3):273-80.
2002: Douglas J Biedenbach; Ronald Jones
Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin.
Diagnostic microbiology and infectious disease 2002;43(4):323-6.
2002: Jeffrey T Kirby; Alan H Mutnick; Ronald Jones; Douglas J Biedenbach; Michael A Pfaller
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
Diagnostic microbiology and infectious disease 2002;43(4):303-9.
2002: Tamara R Anderegg; Douglas J Biedenbach; Ronald Jones
In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
Antimicrobial agents and chemotherapy 2002;46(8):2662-4.
2002: John D Turnidge; Jan Bell; Douglas J Biedenbach; Ronald Jones
Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999.
International journal of antimicrobial agents 2002;20(1):10-7.
2002: Ronald Jones; Jeffrey T Kirby; Mondell L Beach; Douglas J Biedenbach; Michael A Pfaller
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2002;43(3):239-43.
2002: Charles H Ballow; Douglas J Biedenbach; Flavia Rossi; Ronald Jones
Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS).
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2002;6(3):100-9.
2002: Kelley A Gordon; Mondell L Beach; Douglas J Biedenbach; Ronald Jones; Paul R Rhomberg; Alan H Mutnick
Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2002;43(2):157-62.
2002: W Howard; Douglas J Biedenbach; Ronald Jones
Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002;8(6):340-4.
2002: Tamara R Anderegg; Douglas J Biedenbach; Ronald Jones
In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci.
The Journal of antimicrobial chemotherapy 2002;49(6):1019-21.
2002: Charles H Ballow; Ronald Jones; Douglas J Biedenbach
A multicenter evaluation of linezolid antimicrobial activity in North America.
Diagnostic microbiology and infectious disease 2002;43(1):75-83.
2002: Alan H Mutnick; Douglas J Biedenbach; John D Turnidge; Ronald Jones
Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
Diagnostic microbiology and infectious disease 2002;43(1):65-73.
2002: David M Johnson; Douglas J Biedenbach; Ronald Jones
Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
Diagnostic microbiology and infectious disease 2002;43(1):49-60.
2002: Ronald Jones; Phyllis Della-Latta; Lillian V Lee; Douglas J Biedenbach
Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2002;42(2):137-9.
2002: Ronald Jones; Douglas J Biedenbach; Tamara R Anderegg
In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.
Diagnostic microbiology and infectious disease 2002;42(2):119-22.
2001: Douglas J Biedenbach; Ronald Jones
Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains.
Diagnostic microbiology and infectious disease 2001;41(4):225-8.
2001: Michael A Pfaller; Ronald Jones; Douglas J Biedenbach
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).
Diagnostic microbiology and infectious disease 2001;41(4):177-82.
2001: Kelley A Gordon; J Fusco; Douglas J Biedenbach; Michael A Pfaller; Ronald Jones
Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program.
Antimicrobial agents and chemotherapy 2001;45(12):3599-600.
2001: Lalitagauri M Deshpande; Douglas J Biedenbach; Ronald Jones
Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods.
International journal of antimicrobial agents 2001;18(5):437-40.
2001: Douglas J Biedenbach; Mondell L Beach; Ronald Jones
In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Diagnostic microbiology and infectious disease 2001;40(4):173-7.
2001: A M Fix; Michael A Pfaller; Douglas J Biedenbach; Mondell L Beach; Ronald Jones
Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development.
International journal of antimicrobial agents 2001;18(2):141-5.
2001: M F Rospide; Douglas J Biedenbach; Ronald Jones
Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae.
International journal of antimicrobial agents 2001;17(6):451-5.
2001: Ronald Jones; Douglas J Biedenbach
Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001).
Diagnostic microbiology and infectious disease 2001;40(1-2):71-3.
2001: Ronald Jones; C H Ballow; Douglas J Biedenbach
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
Diagnostic microbiology and infectious disease 2001;40(1-2):59-66.
2001: Paul R Rhomberg; Douglas J Biedenbach; Ronald Jones
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
Diagnostic microbiology and infectious disease 2001;40(1-2):45-9.
2001: Douglas J Biedenbach; Ronald Jones; Michael A Pfaller
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Diagnostic microbiology and infectious disease 2001;39(4):245-50.
2001: Ana Gales; Douglas J Biedenbach; Patricia L Winokur; D M Hacek; Michael A Pfaller; Ronald Jones
Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme.
Diagnostic microbiology and infectious disease 2001;39(2):125-7.
2001: Douglas J Biedenbach; Ronald Jones
In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods.
Diagnostic microbiology and infectious disease 2001;39(1):49-53.
2000: Ronald Jones; Douglas J Biedenbach; DM Johnson
Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.
Diagnostic microbiology and infectious disease 2000;37(2):143-6.
2000: DM Johnson; Douglas J Biedenbach; Mondell L Beach; Michael A Pfaller; Ronald Jones
Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Diagnostic microbiology and infectious disease 2000;37(2):99-105.
2000: Douglas J Biedenbach; Ronald Jones
Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).
Diagnostic microbiology and infectious disease 2000;36(4):255-9.
2000: Sujata M Bhavnani; J A Drake; Alan Forrest; JA Deinhart; Ronald Jones; Douglas J Biedenbach; CH Ballow
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.
Diagnostic microbiology and infectious disease 2000;36(3):145-58.
2000: Shan Putnam; Gregory C Gray; Douglas J Biedenbach; Ronald Jones
Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2000;6(1):2-8.
1999: Douglas J Biedenbach; DM Johnson; Ronald Jones
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):325-31.
1999: MT Lewis; Douglas J Biedenbach; Ronald Jones
In vitro evaluation of broad-spectrum beta-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):317-23.
1999: MT Lewis; Keizo Yamaguchi; Douglas J Biedenbach; Ronald Jones
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):307-15.
1999: Douglas J Biedenbach; DM Johnson; Ronald Jones
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):299-305.
1999: DM Johnson; Douglas J Biedenbach; Ronald Jones
In vitro evaluation of broad-spectrum beta-lactams in the philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):291-7.
1999: MT Lewis; Douglas J Biedenbach; Ronald Jones
In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):285-90.
1999: Douglas J Biedenbach; MT Lewis; Ronald Jones
In vitro evaluation of cefepime and other broad-spectrum beta-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):277-83.
1999: Ronald Jones; ME Erwin; Douglas J Biedenbach; DM Johnson; Michael A Pfaller
Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
Diagnostic microbiology and infectious disease 1999;35(3):227-34.
1999: Russell Lewis; Michael E Klepser; Erika J Ernst; Brian C Lund; Douglas J Biedenbach; Ronald Jones
Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection.
Antimicrobial agents and chemotherapy 1999;43(8):2005-9.
1999: Douglas J Biedenbach; MA Croco; T J Barrett; Ronald Jones
Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1999;18(6):428-31.
1999: Keizo Yamaguchi; D Mathai; Douglas J Biedenbach; MT Lewis; Ana Gales; Ronald Jones
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):123-34.
1999: Ronald Jones; DM Johnson; ME Erwin; Mondell L Beach; Douglas J Biedenbach; Michael A Pfaller
Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):91-8.
1999: Ronald Jones; Douglas J Biedenbach; ME Erwin; Mondell L Beach; Michael A Pfaller
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
Journal of clinical microbiology 1999;37(6):1999-2002.
1999: KC Kugler; Douglas J Biedenbach; Ronald Jones
Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms.
Diagnostic microbiology and infectious disease 1999;34(1):73-6.
1999: Douglas J Biedenbach; SA Marshall; Ronald Jones
Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System.
Diagnostic microbiology and infectious disease 1999;33(4):305-7.
1999: Douglas J Biedenbach; Ronald Jones; MT Lewis; MA Croco; MS Barrett
Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Diagnostic microbiology and infectious disease 1999;33(4):275-82.
1999: Ronald Jones; KC Kugler; ME Erwin; Douglas J Biedenbach; Mondell L Beach; Michael A Pfaller
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;33(4):247-53.
1998: Douglas J Biedenbach; Mondell L Beach; Ronald Jones
Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains.
Diagnostic microbiology and infectious disease 1998;32(4):307-11.
1998: MA Croco; Douglas J Biedenbach; Michael A Pfaller; G V Doern; Ronald Jones
In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.
The Journal of antimicrobial chemotherapy 1998;42(5):672-3.
1998: Ronald Jones; Douglas J Biedenbach; SA Marshall; Michael A Pfaller; G V Doern
Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.
Diagnostic microbiology and infectious disease 1998;32(2):107-10.
1998: Douglas J Biedenbach; MS Barrett; MA Croco; Ronald Jones
BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Diagnostic microbiology and infectious disease 1998;32(1):45-50.
1998: Ronald Jones; Douglas J Biedenbach; MA Croco; MS Barrett
In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 1998;31(4):573-8.
1998: Ronald Jones; CH Ballow; Douglas J Biedenbach; JA Deinhart; Jerome J Schentag
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Diagnostic microbiology and infectious disease 1998;31(3):437-51.
1998: Douglas J Biedenbach; MS Barrett; Ronald Jones
Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.
Diagnostic microbiology and infectious disease 1998;31(2):349-53.
1997: Douglas J Biedenbach; Ronald Jones
Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.
Journal of clinical microbiology 1997;35(12):3198-202.
1997: F Marco; Douglas J Biedenbach; Ronald Jones
Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation.
Diagnostic microbiology and infectious disease 1997;29(1):55-7.
1997: C Jamjian; Douglas J Biedenbach; Ronald Jones
In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.
Antimicrobial agents and chemotherapy 1997;41(2):454-9.
1997: Ronald Jones; Douglas J Biedenbach
Antimicrobial activity of RU-66647, a new ketolide.
Diagnostic microbiology and infectious disease 1997;27(1-2):7-12.
1997: Douglas J Biedenbach; I H Schermer; Ronald Jones
Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices.
Diagnostic microbiology and infectious disease 1997;27(1-2):1-5.
1996: Douglas J Biedenbach; Ronald Jones
Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: investigation using 510(k) review criteria, recommended by the Food and Drug Administration.
Journal of clinical microbiology 1996;34(12):3214-7.
1996: L Zerva; Douglas J Biedenbach; Ronald Jones
Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
Journal of clinical microbiology 1996;34(8):1970-4.
1996: Douglas J Biedenbach; Ronald Jones
The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci.
Diagnostic microbiology and infectious disease 1996;25(1):47-51.
1995: Ronald Jones; DM Johnson; Douglas J Biedenbach; SA Marshall
Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
Diagnostic microbiology and infectious disease 1995;23(3):123-7.
1995: Douglas J Biedenbach; L D Sutton; Ronald Jones
Antimicrobial activity of CS-940, a new trifluorinated quinolone.
Antimicrobial agents and chemotherapy 1995;39(10):2325-30.
1995: Helio S Sader; Douglas J Biedenbach; Ronald Jones
Evaluation of Vitek and API 20S for species identification of enterococci.
Diagnostic microbiology and infectious disease 1995;22(4):315-9.
1995: Douglas J Biedenbach; Ronald Jones
In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.
Antimicrobial agents and chemotherapy 1995;39(7):1636-42.
1995: L D Sutton; Douglas J Biedenbach; A Yen; Ronald Jones
Development, characterization, and initial evaluations of S1. A new chromogenic cephalosporin for beta-lactamase detection.
Diagnostic microbiology and infectious disease 1995;21(1):1-8.
1994: Ronald Jones; MS Barrett; Douglas J Biedenbach
Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
Diagnostic microbiology and infectious disease 1994;19(2):93-9.
1994: Douglas J Biedenbach; Ronald Jones
Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef.
Journal of clinical microbiology 1994;32(2):559-62.
1993: J H Hughes; Douglas J Biedenbach; ME Erwin; Ronald Jones
E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates.
Journal of clinical microbiology 1993;31(12):3255-9.
1993: Douglas J Biedenbach; Ronald Jones; ME Erwin
Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.
Journal of clinical microbiology 1993;31(10):2828-30.